Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
89.9 EUR | +0.48% | +2.02% | -0.36% |
Jun. 27 | CAC40: caution prevails ahead of crucial deadlines | CF |
Jun. 27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.36% | 120B | - | ||
+56.63% | 819B | C+ | ||
-6.47% | 351B | C+ | ||
+18.32% | 329B | B- | ||
+9.33% | 298B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 225B | A+ | ||
+13.31% | 217B | B- | ||
+8.28% | 168B | C+ | ||
-2.90% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi